Devita, Hellman, and Rosenberg's Cancer

LWBK1006-24 LWW-Govindan-Review December 12, 2011 19:15

Chapter 24•Cancer of the Breast 337

Question 24.32. You are seeing a 52-year-old woman with newly diagnosed stage III breast

cancer (5.5 cm tumor, 6+LN, grade 3, ER–/PR–/HER2+by FISH with

ratio 8.7). She asks about the benefits of trastuzumab. On the basis of the

updated analysis of the Intergroup adjuvant trials (N9831 and B31), you

tell her that the addition of trastuzumab to adjuvant ACT chemotherapy:

A. Improves relative DFS by 35%

B. Improves relative OS by 40%

C. Reduces the probability of distant recurrence by 50%

D. Results in death from congestive heart failure in 5%

Question 24.33. On the basis of the overview analysis, the relative benefits of adjuvant

chemotherapy are:

A. Independent of ER status

B. Independent of administration of hormone therapy

C. Greater with anthracycline compared with CMF-type regimens

D. All of the above

Question 24.34. Identify the correct statement regarding the use of taxanes in the adjuvant

setting:

A. Concurrent administration with anthracyclines provides superior effi-

cacy compared with sequential regimens.

B. Sequential anthracycline>taxane therapy is superior to anthracy-

cline therapy alone.

C. Docetaxel administered every 3 weeks has greater efficacy than pacli-

taxel administered weekly.

D. Incorporation of taxanes into adjuvant therapy increases the risk of

cardiotoxicity.

Question 24.35. The addition of bevacizumab to paclitaxel as initial chemotherapy for

metastatic breast cancer increases all of the following, EXCEPT:

A. DFS

B. OS

C. Response rate

D. Hypertension

Question 24.36. The addition of lapatinib to capecitabine in patients with advanced

HER2+breast cancer increases all of the following, EXCEPT:

A. Time to progression (TTP)

B. Rash

C. Diarrhea

D. OS